Gene editing and cell therapy research by Caribou Biosciences
Capital shortage prompts Caribou Biosciences to halt allogeneic CAR-T therapy initiatives
Caribou Biosciences announced it will discontinue its allogeneic CAR-T cell therapy programs due to difficulties in securing the necessary funding to advance these initiatives. The company stated ...
Caribou Biosciences named finalist for 2026 Best Oncology R and D Advance for vispa-cel
Caribou Biosciences has been selected as a finalist for Citeline's 2026 Best Oncology R and D Advance Award for its vispa-cel therapy. The recognition highlights vispa-cel, a pivotal-ready ...
Second quarter revenue and strategy update from Caribou Biosciences
Caribou Biosciences has released its financial results for the second quarter of 2026, accompanied by a comprehensive update on its ongoing business operations. The company, active in the gene ...
Caribou Biosciences secures e-poster spot for ANTLER abstract at PPLC 2026
Caribou Biosciences announced that its ANTLER abstract has been accepted as an e-poster for PPLC 2026. The abstract, which features previously presented data on vispa-cel, will be accessible via ...
Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026
Caribou Biosciences announced that Dr. Binod Dhakal will present longer follow-up data on CB-011 from the dose escalation segment of the CaMMouflage phase 1 trial in relapsed or refractory ...
Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA
Caribou Biosciences has presented new data on its allogeneic CAR-T cell programs, targeting lymphoma and multiple myeloma at the EHA congress. The company continues to advance its pipelines, with ...
CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update
Caribou Biosciences has released updated follow-up data from its dose escalation study of CB-011 in patients with relapsed or refractory multiple myeloma. The latest findings will be presented ...
Caribou Biosciences prepares to attend Jefferies Global Healthcare Conference in New York
Caribou Biosciences announced its participation in the upcoming Jefferies Global Healthcare Conference in New York. The company will join leading industry players to discuss innovation in cell ...
Caribou Biosciences brings CMO and CFO to BioConnect Investor Conference fireside chat
Caribou Biosciences will be participating in the HCWCO 4th Annual BioConnect Investor Conference, offering an in-depth fireside chat featuring Chief Medical Officer Tina Albertson and Chief ...
Caribou Biosciences attends BioConnect Investor Conference in New York next week
Caribou Biosciences announced that it will participate in the 4th Annual BioConnect Investor Conference hosted by H.C. Wainwright in New York City next week. The event brings together leading ...
EHA2026 spotlights Caribou Biosciences advances in allogeneic CAR-T treatments for lymphoma and multiple myeloma
Caribou Biosciences announced that it will deliver two oral presentations at EHA2026 to reveal advancements in its allogeneic CAR-T cell therapy programs for blood cancers. The presentations will ...
Caribou Biosciences CEO Rachel Haurwitz to join Bank of America conference fireside chat
Caribou Biosciences is set to have its president and CEO, Rachel Haurwitz, PhD, participate in an upcoming fireside chat at the Bank of America Securities Health Care Conference. The discussion ...
Caribou Biosciences to participate in BofA Securities Health Care event in Las Vegas
Caribou Biosciences announced that its president and CEO, Rachel Haurwitz, PhD, will take part in a fireside chat at the BofA Securities Health Care Conference in Las Vegas next week. The ...
